464898-19-9

Basic information

• Product Name: (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol
• Synonyms: (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol
• CAS NO: 464898-19-9
• Molecular Weight: 249.353
• Mol File: 464898-19-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol(464898-19-9)
• EPA Substance Registry System: (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol(464898-19-9)

Safety Data

• Hazardous Substances Data: 464898-19-9(Hazardous Substances Data)

Upstream product

• 1458-63-5 N-(3-chloropropyl)-piperidine 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 110-89-4 piperidine 
• 104-58-5 3-piperidinopropan-1-ol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 82625-46-5 4-(3-(piperidin-1-yl)propoxy)benzaldehyde 
• 93543-57-8 3-piperidin-1-yl-propylamine hydrochloride 
• 69076-29-5 4-(3-chloropropoxy)benzoic acid methyl ester 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 5472-49-1 1-(3-chloropropyl)piperidine hydrochloride 

Downstream Products

• 914303-42-7 (4-(3-(piperidin-1-yl)propoxy)phenyl)methanol hydrochloride 

Relevant articles and documents

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness

Several hH3R antagonists/inverse agonists entered clinical phases for a broad spectrum of mainly centrally occurring diseases. Nevertheless, many promising candidates failed due to their pharmacokinetic profile, mostly because of their strong lipophilicity and their dibasic character. Analysis of previously, as potential PET ligands synthesized compounds (ST-889, ST-928) revealed promising results concerning physicochemical properties and drug-likeness. Herein, the synthesis, the evaluation of the binding properties at the hH3R and the estimation of different physicochemical and drug-likeness properties of further novel benzylpiperidine variations on H3R antagonists is described. Due to the introduction of various small hydrophilic moieties in the structure, drug-likeness parameters have been improved. For instance, compound 12 (ST-1032) showed in addition to high affinity at the H3R (pKi (hH3R) = 9.3) c log S, c log P, LE, LipE, and LELP values of -2.48, 2.18, 0.44, 7.14, and 4.95, respectively. Also, the keto derivative 5 (ST-1703, pKi (hH 3R) = 8.6) revealed LipE and LELP values of 5.25 and 6.84, respectively.

First metal-containing histamine H3 receptor ligands

Iron-containing ligands targeting the human histamine H3 receptor (hH3R) were prepared. The compounds contain ferrocene sandwich complexes coupled via different linkers to a basic hH3R antagonist/inverse agonist pharmacophore. In a click chemistry approach, a triazole was successfully inserted as a new linking element. Two ferrocenylmethylamines and a ferrocenyltriazole were the most affine hH 3R ligands within this series, showing receptor binding in the nano- and subnanomolar concentration range.